CAR-T Meeting 2023 | CAR-T versus autoSCT in NHL: recent data and future outlooks
Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, shares some insights into the growing use of CAR-T therapy in non-Hodgkin lymphoma (NHL), highlighting recent trials in this space, and the possibility of shifting away from autologous transplantation (autoSCT) in the future. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BELLICUM PHARMACEUTICALS: Membership on an entity’s Board of Directors or advisory committees
BMS/CELGENE: Speakers Bureau, Membership on an entity’s Board of Directors or advisory committees
EBMT: Membership on an entity’s Board of Directors or advisory committees
FRESENIUS KABI: Research Funding
KITE/GILEAD: Honoraria, Speakers Bureau, Membership on an entity’s Board of Directors or advisory committees
JANSSEN PHARMACEUTICALS: Membership on an entity’s Board of Directors or advisory committees
JAZZ: Honoraria
MILTENYI BIOTECH: Research Funding
NOVARTIS: Speakers Bureau
SANOFI SA: Speakers Bureau, Honoraria, Research Funding
TERUMO BCT: Speakers Bureau
